Antipsychotic drugs suppress the AKT/NF-κB pathway and regulate the differentiation of T-cell subsets

Immunology Letters

Volumn 140, Issue 1-2, 2011, Pages 81-91

  Chen, Mao Liang ^a   Tsai, Tzung Chieh ^b   Lin, Yi Yin ^a   Tsai, Ya Min ^a   Wang, Lu Kai ^c   Lee, Ming Cheng ^a   Tsai, Fu Ming ^a,d  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d SOOCHOW UNIVERSITY   (Taiwan)

Author keywords

AKT; Clozapine; NF B; Risperidone; T cell differentiation

Indexed keywords

CLOZAPINE; GAMMA INTERFERON; HALOPERIDOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN KINASE B; RISPERIDONE; STAT4 PROTEIN; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOREGULATION; LEUKEMIA CELL LINE; LYMPHOCYTE DIFFERENTIATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL;

ANTIPSYCHOTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CLOZAPINE; GATA3 TRANSCRIPTION FACTOR; HALOPERIDOL; HUMANS; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; RISPERIDONE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTE SUBSETS; TH1-TH2 BALANCE;

EID: 80051799948     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.06.011     Document Type: Article

References (53)

1. Erbagci A.B., Herken H., Koyluoglu O., Yilmaz N., Tarakcioglu M. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 2001, 10:109-115.
2. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y., Shen Y.C. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 2004, 65:940-947.
3. Ganguli R., Brar J.S., Solomon W., Chengappa K.N., Rabin B.S. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res 1992, 44:113-123.
4. Kim D.J., Kim W., Yoon S.J., Go H.J., Choi B.M., Jun T.Y., et al. Effect of risperidone on serum cytokines. Int J Neurosci 2001, 111:11-19.
5. Cazzullo C.L., Sacchetti E., Galluzzo A., Panariello A., Adorni A., Pegoraro M., et al. Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:33-39.
6. Ukai W., Ozawa H., Tateno M., Hashimoto E., Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm 2004, 111:667-681.
7. Kang U.G., Seo M.S., Roh M.S., Kim Y., Yoon S.C., Kim Y.S. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett 2004, 560:115-119.
8. Shin S.Y., Choi B.H., Ko J., Kim S.H., Kim Y.S., Lee Y.H. Clozapine, a neuroleptic agent, inhibits Akt by counteracting Ca2+/calmodulin in PTEN-negative U-87MG human glioblastoma cells. Cell Signal 2006, 18:1876-1886.
9. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002, 2:664-674.
10. Saldana M., Bonastre M., Aguilar E., Marin C. Role of nigral NFkappaB p50 and p65 subunit expression in haloperidol-induced neurotoxicity and stereotyped behavior in rats. Eur Neuropsychopharmacol 2006, 16:491-497.
11. Post A., Holsboer F., Behl C. Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants. J Neurosci 1998, 18:8236-8246.
12. Basta-Kaim A., Budziszewska B., Jagla G., Nowak W., Kubera M., Lason W. Inhibitory effect of antipsychotic drugs on the Con A- and LPS-induced proliferative activity of mouse splenocytes: a possible mechanism of action. J Physiol Pharmacol 2006, 57:247-264.
13. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998, 8:275-283.
14. Frucht D.M., Aringer M., Galon J., Danning C., Brown M., Fan S., et al. Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol 2000, 164:4659-4664.
15. Mullen A.C., High F.A., Hutchins A.S., Lee H.W., Villarino A.V., Livingston D.M., et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 2001, 292:1907-1910.
16. Murphy K.M., Ouyang W., Szabo S.J., Jacobson N.G., Guler M.L., Gorham J.D., et al. T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases. Curr Top Microbiol Immunol 1999, 238:13-26.
17. Nishikomori R., Usui T., Wu C.Y., Morinobu A., O'Shea J.J., Strober W. Activated STAT4 has an essential role in Th1 differentiation and proliferation that is independent of its role in the maintenance of IL-12R beta 2 chain expression and signaling. J Immunol 2002, 169:4388-4398.
18. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100:655-669.
19. Stevens L., Htut T.M., White D., Li X., Hanidu A., Stearns C., et al. Involvement of GATA3 in protein kinase C theta-induced Th2 cytokine expression. Eur J Immunol 2006, 36:3305-3314.
20. Yamashita M., Ukai-Tadenuma M., Miyamoto T., Sugaya K., Hosokawa H., Hasegawa A., et al. Essential role of GATA3 for the maintenance of type 2 helper T (Th2) cytokine production and chromatin remodeling at the Th2 cytokine gene loci. J Biol Chem 2004, 279:26983-26990.
21. Zheng W., Flavell R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4T cells. Cell 1997, 89:587-596.
22. Lee K., Gudapati P., Dragovic S., Spencer C., Joyce S., Killeen N., et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010, 32:743-753.
23. Riedel M., Schwarz M.J., Strassnig M., Spellmann I., Muller-Arends A., Weber K., et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 2005, 255:261-268.
24. Mauri M.C., Volonteri L.S., Colasanti A., Fiorentini A., De Gaspari I.F., Bareggi S.R. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007, 46:359-388.
25. Magliozzi J.R., Hollister L.E., Arnold K.V., Earle G.M. Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry 1981, 138:365-367.
26. Megens A.A., Awouters F.H., Schotte A., Meert T.F., Dugovic C., Niemegeers C.J., et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 1994, 114:9-23.
27. Das J., Chen C.H., Yang L., Cohn L., Ray P., Ray A. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2001, 2:45-50.
28. Maneechotesuwan K., Xin Y., Ito K., Jazrawi E., Lee K.Y., Usmani O.S., et al. Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. J Immunol 2007, 178:2491-2498.
29. Seki N., Miyazaki M., Suzuki W., Hayashi K., Arima K., Myburgh E., et al. IL-4-induced GATA-3 expression is a time-restricted instruction switch for Th2 cell differentiation. J Immunol 2004, 172:6158-6166.
30. Yin J., Albert R.H., Tretiakova A.P., Jameson B.A. 5-HT(1B) receptors play a prominent role in the proliferation of T-lymphocytes. J Neuroimmunol 2006, 181:68-81.
31. Ameisen J.C., Meade R., Askenase P.W. A new interpretation of the involvement of serotonin in delayed-type hypersensitivity. Serotonin-2 receptor antagonists inhibit contact sensitivity by an effect on T cells. J Immunol 1989, 142:3171-3179.
32. Laberge S., Cruikshank W.W., Beer D.J., Center D.M. Secretion of IL-16 (lymphocyte chemoattractant factor) from serotonin-stimulated CD8+ T cells in vitro. J Immunol 1996, 156:310-315.
33. Li Q., Verma I.M. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002, 2:725-734.
34. Rao A., Luo C., Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997, 15:707-747.
35. Muller T., Durk T., Blumenthal B., Grimm M., Cicko S., Panther E., et al. 5-Hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 2009, 4:e6453.
36. Levite M., Chowers Y., Ganor Y., Besser M., Hershkovits R., Cahalon L. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. Eur J Immunol 2001, 31:3504-3512.
37. Basu B., Sarkar C., Chakroborty D., Ganguly S., Shome S., Dasgupta P.S., et al. D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells. J Biol Chem 2010, 285:27026-27032.
38. Sarkar C., Das S., Chakroborty D., Chowdhury U.R., Basu B., Dasgupta P.S., et al. Stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J Immunol 2006, 177:7525-7529.
39. Nakano K., Higashi T., Takagi R., Hashimoto K., Tanaka Y., Matsushita S. Dopamine released by dendritic cells polarizes Th2 differentiation. Int Immunol 2009, 21:645-654.
40. Zimbroff D.L., Kane J.M., Tamminga C.A., Daniel D.G., Mack R.J., Wozniak P.J., et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 1997, 154:782-791.
41. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 1996, 277:968-981.
42. Palfreyman M.G., Schmidt C.J., Sorensen S.M., Dudley M.W., Kehne J.H., Moser P., et al. Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology (Berl) 1993, 112:S60-S67.
43. Fiorentini C., Guerra N., Facchetti M., Finardi A., Tiberio L., Schiaffonati L., et al. Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB. Mol Endocrinol 2002, 16:353-366.
44. Yang M., Zhang H., Voyno-Yasenetskaya T., Ye R.D. Requirement of Gbetagamma and c-Src in D2 dopamine receptor-mediated nuclear factor-kappaB activation. Mol Pharmacol 2003, 64:447-455.
45. Ouyang W., Lohning M., Gao Z., Assenmacher M., Ranganath S., Radbruch A., et al. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 2000, 12:27-37.
46. Riedel M., Spellmann I., Schwarz M.J., Strassnig M., Sikorski C., Moller H.J., et al. cellular immune response in schizophrenic patients. J Psychiatr Res 2007, 41:3-7.
47. Accomando S., Fragapane M.L., Montaperto D., Trizzino A., Amato G.M., Calderone F., et al. Coeliac disease and depression: two related entities?. Dig Liver Dis 2005, 37:298-299.
48. Garud S., Leffler D., Dennis M., Edwards-George J., Saryan D., Sheth S., et al. Interaction between psychiatric and autoimmune disorders in coeliac disease patients in the Northeastern United States. Aliment Pharmacol Ther 2009, 29:898-905.
49. Ludvigsson J.F., Reutfors J., Osby U., Ekbom A., Montgomery S.M. Coeliac disease and risk of mood disorders-a general population-based cohort study. J Affect Disord 2007, 99:117-126.
50. Johrens K., Anagnostopoulos I., Stein H. T-bet expression patterns in coeliac disease, cryptic and overt enteropathy-type T-cell lymphoma. Histopathology 2005, 47:368-374.
51. Monteleone I., Monteleone G., Del Vecchio Blanco G., Vavassori P., Cucchiara S., MacDonald T.T., et al. Regulation of the T helper cell type 1 transcription factor T-bet in coeliac disease mucosa. Gut 2004, 53:1090-1095.
52. Salvati V.M., MacDonald T.T., Bajaj-Elliott M., Borrelli M., Staiano A., Auricchio S., et al. Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut 2002, 50:186-190.
53. Cazzullo C.L., Sacchetti E., Galluzzo A., Panariello A., Colombo F., Zagliani A., et al. Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res 2001, 47:293-298.